TNXP vs. ORGS, AYTU, GLYC, TLPH, NRSN, NERV, GLTO, KALA, VBIV, and TRAW
Should you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Orgenesis (ORGS), Aytu BioPharma (AYTU), GlycoMimetics (GLYC), Talphera (TLPH), NeuroSense Therapeutics (NRSN), Minerva Neurosciences (NERV), Galecto (GLTO), KALA BIO (KALA), VBI Vaccines (VBIV), and Traws Pharma (TRAW). These companies are all part of the "pharmaceutical preparations" industry.
Orgenesis (NASDAQ:ORGS) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, community ranking, dividends, risk and analyst recommendations.
Tonix Pharmaceuticals has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,343.97%. Orgenesis' return on equity of -83.03% beat Tonix Pharmaceuticals' return on equity.
22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by company insiders. Comparatively, 0.5% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Tonix Pharmaceuticals received 338 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 63.72% of users gave Tonix Pharmaceuticals an outperform vote.
Orgenesis has higher earnings, but lower revenue than Tonix Pharmaceuticals.
In the previous week, Orgenesis had 2 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 4 mentions for Orgenesis and 2 mentions for Tonix Pharmaceuticals. Orgenesis' average media sentiment score of 0.12 beat Tonix Pharmaceuticals' score of -0.55 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.
Tonix Pharmaceuticals has a consensus target price of $5.50, indicating a potential upside of 3,077.35%. Given Orgenesis' higher probable upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than Orgenesis.
Orgenesis has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.
Summary
Tonix Pharmaceuticals beats Orgenesis on 10 of the 15 factors compared between the two stocks.
Get Tonix Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tonix Pharmaceuticals Competitors List
Related Companies and Tools
